Immuron Limited (IMRN)
| Market Cap | 27.17M |
| Revenue (ttm) | 1.74M |
| Net Income (ttm) | -2.02M |
| Shares Out | 5.60M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 26 |
| Last Price | $4.85 |
| Previous Close | $4.83 |
| Change ($) | 0.02 |
| Change (%) | 0.42% |
| Day's Open | - |
| Day's Range | 4.85 - 4.85 |
| Day's Volume | - |
| 52-Week Range | 4.63 - 12.68 |
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutic...
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics...
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing ora...
Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.
Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered d...
Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome cor...
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut...
The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.
The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday
Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu...
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Comp...
Key Highlights:
MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...
Key Highlights:
Shares of thinly traded nano-cap biotech IMMURON LTD/S ADR (NASDAQ: IMRN) were off to a flying start Wednesday morning.
Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose sharply Wednesday on roughly 250 times average volume.
About IMRN
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alc... [Read more...]
| Industry Biotechnology | Founded 1994 |
| Stock Exchange NASDAQ | Ticker Symbol IMRN |
Financial Performance
In 2020, Immuron's revenue was 2.52 million, an increase of 5.49% compared to the previous year's 2.39 million. Losses were -2.93 million, -37.14% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Immuron is 6.41, which is an increase of 32.16% from the latest price.